Detalles de la búsqueda
1.
MED12 controls the response to multiple cancer drugs through regulation of TGF-ß receptor signaling.
Cell
; 151(5): 937-50, 2012 Nov 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-23178117
2.
B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
Breast Cancer Res
; 25(1): 117, 2023 10 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37794508
3.
MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients.
Genes Chromosomes Cancer
; 61(3): 148-160, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34841595
4.
BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance.
Breast Cancer Res Treat
; 195(3): 263-274, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35984580
5.
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.
Int J Cancer
; 147(8): 2303-2315, 2020 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32270478
6.
Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
Curr Oncol Rep
; 18(7): 44, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27241520
7.
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.
J Pathol
; 230(3): 270-6, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23661334
8.
Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial.
JCO Precis Oncol
; 8: e2200667, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38237097
9.
Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort.
JCO Precis Oncol
; 7: e2200670, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37738542
10.
Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
Eur J Cancer
; 167: 92-102, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35421703
11.
Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant.
NPJ Breast Cancer
; 8(1): 71, 2022 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35676284
12.
Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.
Transl Oncol
; 13(4): 100756, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32208353
13.
Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.
PLoS One
; 15(7): e0235766, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32639993
14.
MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology.
J Mol Diagn
; 21(5): 808-823, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31173928
15.
Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.
Transl Oncol
; 12(12): 1557-1565, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31513983
16.
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.
Oncoimmunology
; 7(12): e1509820, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30524905
17.
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Clin Cancer Res
; 24(16): 3928-3940, 2018 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29685880
18.
FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.
J Pathol Clin Res
; 2(4): 223-233, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27785367
19.
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
Sci Rep
; 6: 18517, 2016 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26729235
20.
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
J Clin Oncol
; 33(12): 1334-9, 2015 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25559818